Astellas Pharma Inc. (OTCMKTS:ALPMY) Shares Shorted: Short Interest Up 519.9% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 155,427 shares, an increase of 519.9% from the September 15th total of 25,074 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 192,822 shares, the days-to-cover ratio is currently 0.8 days.

Astellas Pharma Stock Up 1.1%

Shares of ALPMY opened at $14.35 on Friday. The firm has a fifty day moving average price of $14.72 and a 200-day moving average price of $14.49. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $25.97 billion, a P/E ratio of 10.92 and a beta of 0.08. Astellas Pharma has a 12-month low of $10.03 and a 12-month high of $17.35.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Astellas Pharma currently has a consensus rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.